Does Amerigroup Cover Prolia?

What Is Prolia and Why Does Coverage Matter?

Prolia is the brand name for denosumab 60 mg, a RANK ligand inhibitor that slows bone resorption and reduces fracture risk. The FDA approved it in 2010 for postmenopausal women with osteoporosis at high risk for fracture, and the drug now carries additional indications for glucocorticoid-induced osteoporosis and bone loss in patients receiving certain cancer treatments [1]. Because Prolia is a biologic administered by injection every six months, its cost sits well above generic oral bisphosphonates like alendronate, which run $10 to $30 per month at most pharmacies.

The FREEDOM trial (N=7,808) demonstrated that denosumab reduced new vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% over 36 months compared with placebo [2]. That fracture-reduction profile makes Prolia a standard second-line option when oral therapy fails or is contraindicated. For Amerigroup members, the practical question is not whether the drug works. It is whether the plan will pay for it before you receive the injection. A denied claim for a single dose can leave a patient responsible for roughly $1,863 at wholesale acquisition cost, so verifying coverage and completing prior authorization before the scheduled injection date is a financial necessity [3].

Amerigroup Coverage by Plan Type

Coverage rules differ depending on whether you hold an Amerigroup Medicaid plan, a Medicare Advantage plan, or a marketplace (ACA) plan. The distinction matters because each product line follows different formulary rules and cost-sharing structures.

Medicaid plans. Amerigroup operates Medicaid managed care contracts in states including Texas, Georgia, Florida, Tennessee, New Jersey, and others. Under federal Medicaid rules, states must cover FDA-approved drugs from manufacturers that participate in the Medicaid Drug Rebate Program, and Amgen participates for Prolia [4]. Medicaid copays are federally capped. Most Amerigroup Medicaid members pay $0 to $3 per injection, though prior authorization is still required.

Medicare Advantage plans. Prolia administered in a physician's office is typically billed under Medicare Part B as a "medical benefit" rather than a Part D pharmacy benefit. Amerigroup Medicare Advantage plans generally cover Part B drugs with a coinsurance of 20% after the annual deductible, though many plans cap specialty drug costs. The actual out-of-pocket amount ranges from $30 to $150 per injection depending on the specific Amerigroup Medicare Advantage product and whether the member has met their deductible [5].

Marketplace / ACA plans. Where Amerigroup offers ACA-compliant plans, Prolia falls on the specialty tier. Members should expect higher copays or coinsurance (often 25% to 40% of the allowed amount), making patient assistance programs from Amgen worth investigating.

Regardless of plan type, Amerigroup classifies Prolia as a specialty medication requiring prospective utilization review. Do not assume coverage. Confirm it.

Prior Authorization Requirements for Prolia

Amerigroup requires prior authorization for Prolia across virtually all of its plan products. The specific clinical criteria may vary by state contract, but the general framework follows a consistent pattern drawn from widely used pharmacy benefit management protocols.

To meet standard approval criteria, the prescribing provider must document a confirmed diagnosis of osteoporosis, typically defined by a DXA T-score of −2.5 or below at the lumbar spine, femoral neck, or total hip, or a history of fragility fracture [6]. The American Association of Clinical Endocrinologists (AACE) 2020 guidelines define "very high fracture risk" as a T-score of −3.0 or below, a recent fracture within 12 months, fractures while on approved osteoporosis therapy, multiple fractures, or use of drugs that cause bone loss such as long-term glucocorticoids [7].

Step therapy is the second hurdle. Amerigroup typically requires documentation that the patient tried and failed, or is intolerant of, at least one generic oral bisphosphonate (alendronate 70 mg weekly or risedronate 35 mg weekly) for a minimum of 3 to 6 months. "Failure" can mean a new fracture on therapy, continued bone density decline on DXA, or documented adverse effects such as esophagitis, severe GI intolerance, or inability to remain upright for 30 minutes after dosing.

Exceptions to step therapy exist. Patients with esophageal disorders (Barrett's esophagus, esophageal stricture), inability to sit upright, renal impairment with eGFR <30 mL/min (where bisphosphonates are contraindicated), or documented hypocalcemia risk factors may qualify for a step-therapy override [8].

The prior authorization request typically requires: the most recent DXA scan report with T-scores, documentation of bisphosphonate trial and outcome, a FRAX score if available, relevant lab values (serum calcium, 25-hydroxyvitamin D, creatinine/eGFR), and clinical notes explaining medical necessity. Submitting all of these documents together reduces back-and-forth delays.

How to Submit a Prior Authorization to Amerigroup

The prescribing provider's office handles the prior authorization submission. Patients cannot submit directly, but can support the process by ensuring their medical records are current and accessible. Here is the typical workflow.

The provider completes Amerigroup's prior authorization request form, available through the Availity portal or by fax. Requests submitted electronically through Availity generally process faster than faxed forms. Standard (non-urgent) requests are reviewed within 5 to 15 business days under most state Medicaid contracts. Urgent requests, defined as situations where delay could seriously jeopardize the patient's health, must be reviewed within 24 to 72 hours depending on the state [9].

Dr. Andrea Singer, director of bone density services at MedStar Georgetown University Hospital and past president of the National Osteoporosis Foundation, has noted: "The prior authorization burden for osteoporosis medications remains one of the most common barriers to treatment. Many patients who are approved for therapy never receive their first dose because the process takes too long or the paperwork is incomplete" [10].

If Amerigroup requests additional information, the provider has a limited window (usually 5 to 10 business days) to respond before the request is administratively closed. Proactive submission of complete documentation at the outset is the single most effective way to avoid delays.

What to Do If Amerigroup Denies Prolia Coverage

A denial is not the final answer. Amerigroup provides a formal appeals process, and success rates on osteoporosis medication appeals can be meaningful when supported by strong clinical documentation.

Step 1: Review the denial letter. The letter specifies the clinical rationale for denial. Common reasons include insufficient documentation of bisphosphonate failure, missing DXA results, or failure to meet the plan's specific T-score threshold.

Step 2: File a first-level appeal. The provider submits a letter of medical necessity along with any missing documentation. Include specific clinical details: the exact bisphosphonate used, duration of therapy, reason for discontinuation, DXA T-scores with dates, FRAX 10-year fracture probability, and any relevant comorbidities. The Endocrine Society's 2020 clinical practice guideline recommends denosumab as a first-line option for patients at very high fracture risk, which can support the medical necessity argument [11].

Step 3: Request a peer-to-peer review. The prescribing physician can request a phone conversation with Amerigroup's medical director to discuss the case directly. Peer-to-peer reviews often overturn denials that resulted from incomplete paperwork rather than true clinical ineligibility.

Step 4: External review. If internal appeals are exhausted, members in most states can request an independent external review through their state's insurance department or Medicaid fair hearing process. For Medicaid members, federal regulations guarantee the right to a fair hearing [12].

Dr. Michael McClung, founding director of the Oregon Osteoporosis Center, has stated: "Denosumab is one of the most effective antiresorptive agents we have. Restricting access through step therapy when a patient clearly meets criteria for high-risk treatment contradicts the evidence base from FREEDOM and its extension studies" [13].

Estimated Out-of-Pocket Costs With Amerigroup

Prolia's wholesale acquisition cost is approximately $1,863 per injection, or $3,726 per year for the standard every-6-month dosing schedule. What Amerigroup members actually pay depends on plan type and benefit design.

For Medicaid enrollees, federal cost-sharing limits apply. Under the Deficit Reduction Act and subsequent CMS guidance, Medicaid copays for preferred brand drugs are capped at $4 for most beneficiaries, and many states set the Prolia copay at $0 to $3 because it is administered in a provider's office and billed as a medical benefit rather than a pharmacy benefit [14]. Members below 150% of the federal poverty level cannot be charged more than nominal amounts.

Medicare Advantage members face different math. When Prolia is billed under Part B (physician-administered), standard coinsurance is 20% of the Medicare-approved amount after the Part B deductible ($257 in 2025). If the Medicare-approved amount is approximately $1,500 per injection, 20% coinsurance works out to roughly $300 per dose before any plan-specific copay caps or supplemental coverage. Many Amerigroup Medicare Advantage plans cap specialty drug copays at lower amounts, but members should verify their specific plan's Summary of Benefits [5].

Amgen's Prolia Patient Assistance Program may cover the full cost for uninsured patients or those with financial hardship. The program requires household income documentation and is available through Amgen's Safety Net Foundation [15]. Separately, commercially insured patients (not Medicaid or Medicare) may qualify for a copay card that reduces out-of-pocket costs to as little as $0 per injection, subject to annual caps.

Clinical Indications That Strengthen Your Coverage Case

Not every osteoporosis diagnosis carries equal weight in a prior authorization review. Certain clinical scenarios make approval more likely because they align with FDA labeling and guideline recommendations.

Postmenopausal osteoporosis with high fracture risk. This is Prolia's primary FDA-approved indication. The FREEDOM trial enrolled postmenopausal women aged 60 to 90 with T-scores between −2.5 and −4.0 and demonstrated a 68% reduction in vertebral fractures over 3 years [2]. Patients whose profile matches the FREEDOM enrollment criteria have the strongest coverage argument.

Glucocorticoid-induced osteoporosis. Prolia received FDA approval for this indication in 2018, based on a head-to-head trial against risedronate showing superior BMD gains at the lumbar spine (3.8% vs. 0.8% at 12 months) [16]. Patients on prednisone 7.5 mg/day or higher for 3 months or more who cannot tolerate oral bisphosphonates fit this category.

Bone loss in men receiving androgen deprivation therapy (ADT) for prostate cancer. The FDA approved Prolia for this use based on a trial (N=1,468) demonstrating a 62% reduction in new vertebral fractures at 36 months in men on ADT [17]. This indication is particularly relevant for Amerigroup members receiving cancer treatment.

Bone loss in women receiving aromatase inhibitor therapy for breast cancer. A separate FDA-approved indication supported by the ABCSG-18 trial (N=3,425), which showed a 50% reduction in clinical fractures with denosumab in women on aromatase inhibitors [18].

When submitting prior authorization, the provider should specify which FDA-approved indication applies and reference the supporting trial data. Generic requests for "osteoporosis treatment" are weaker than precise clinical framing.

Alternatives If Coverage Is Denied or Delayed

If Amerigroup ultimately denies Prolia coverage, or if the prior authorization process creates an unacceptable treatment gap, several alternatives exist.

Generic alendronate (70 mg weekly) remains the most widely covered first-line osteoporosis treatment across all Amerigroup plan types. The Fracture Intervention Trial (FIT) showed alendronate reduced hip fractures by 51% in women with existing vertebral fractures [19]. Cost is typically $4 to $15 per month with insurance.

Zoledronic acid (Reclast) 5 mg IV once yearly is another option. The HORIZON-PFT trial (N=7,765) demonstrated a 70% reduction in vertebral fractures and 41% reduction in hip fractures over 3 years [20]. Because it is administered intravenously in a clinical setting, it bypasses the GI tolerability issues that limit oral bisphosphonates. Amerigroup generally covers zoledronic acid with prior authorization, and it may face fewer step-therapy barriers than Prolia because generic IV zoledronic acid is available at substantially lower cost.

Raloxifene (Evista) is an oral selective estrogen receptor modulator that reduces vertebral (but not hip) fracture risk by 30% at 3 years [21]. It is available generically and sits on lower formulary tiers.

For patients at very high fracture risk who need anabolic therapy, teriparatide (Forteo, now available as generic) and romosozumab (Evenity) are options, though both face their own prior authorization requirements and higher costs.

Discontinuation Risks: Why Coverage Gaps Are Dangerous

One clinical concern specific to Prolia is the well-documented rebound effect when therapy is stopped abruptly. The FREEDOM extension study and subsequent analyses showed that discontinuation of denosumab leads to rapid bone density loss and a spike in vertebral fracture risk, with multiple vertebral fractures reported in some patients within 7 to 12 months of the last dose [22].

The European Calcified Tissue Society (ECTS) issued a position statement recommending that patients who discontinue denosumab should transition to an oral or IV bisphosphonate to prevent rebound bone loss [23]. This rebound risk makes coverage continuity especially important. A gap in Prolia coverage due to a lapsed prior authorization, a plan change during open enrollment, or a transition between Medicaid and Medicare can create a dangerous treatment interruption.

Patients approaching a plan transition should work with their provider to obtain prior authorization on the new plan at least 30 days before the next scheduled injection. If a coverage gap is unavoidable, starting a bisphosphonate bridge (alendronate 70 mg weekly or a single dose of zoledronic acid 5 mg IV) 6 months after the last Prolia injection can mitigate rebound risk.

Navigating State-Specific Amerigroup Medicaid Rules

Amerigroup operates under different Medicaid managed care contracts in each state, and prior authorization criteria can vary. In Texas, Amerigroup follows the Texas Medicaid preferred drug list, which places Prolia in a non-preferred tier requiring prior authorization with documented bisphosphonate failure. In Georgia, the state's fee-for-service Medicaid PDL influences Amerigroup's formulary, and similar step-therapy requirements apply [24].

The practical takeaway: do not rely on a single national coverage policy. The provider's office should contact Amerigroup's pharmacy services line for the member's specific state to confirm current prior authorization criteria. The phone number is on the back of the member's Amerigroup ID card. Providers can also check Availity or the Amerigroup provider portal for state-specific formulary documents and prior authorization forms.

Members who are transitioning between states should be aware that Prolia coverage status, copay amounts, and prior authorization requirements may all change with the new state's Medicaid contract. Requesting a coverage determination from the new state's Amerigroup plan before relocating prevents treatment interruptions.